BioWorld Today: Clinic Roundup-Veloxis Pharmaceuticals A/S
May 21, 2013 - BioWorld Today
Veloxis Pharmaceuticals A/S of Horsholm, Denmark, said data from the STRATO study demonstrated the potential for LCP-Tacro to improve tacrolimus-induced tremors in stable kidney transplant patients. The study, Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO), was presented at the 13th American Transplant Congress in Seattle. In the open-label trial, 44 kidney transplant patients who were stable on twicedaily tacrolimus and had a complaint of hand tremor were switched to once-daily LCP-Tacro. Tremor was evaluated by independent neurologists using a validated rating scale (the FTM scale) and by an objective measurement of tremor frequency and amplitude by Tremorometer. In addition, the patients and the clinicians separately assessed global sense of improvement following the switch to LCP-Tacro. Both the patient- and physician-reported global assessments demonstrated signifi cant overall improvements following the switch to LCP-Tacro (p < 0.001). Most patients in the study are continuing on a long-term extension phase of the study, receiving LCP-Tacro.